Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 6/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | IKBKB | O14920 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5404510 | 0.93 | FLT3 (0.48) | FLT3ADORA3IKBKBBACE1BACE2 | |
| SCHEMBL5398375 | 0.81 | FLT3 (0.41) | FLT3ADORA3TTK | |
| SCHEMBL3469924 | 0.81 | FLT3 (0.55) | FLT3ADORA3BACE1BACE2TTK | |
| SCHEMBL8240750 | 0.79 | FLT3 (0.35) | FLT3HCRTR2 | |
| SCHEMBL12272862 | 0.79 | FLT3 (0.42) | FLT3ADORA3TTK | |
| SCHEMBL9937301 | 0.78 | TTK (0.57) | FLT3ADORA3TTK | |
| SCHEMBL5398296 | 0.77 | ADORA3 (0.53) | FLT3ADORA3HCRTR2 | |
| SCHEMBL5397247 | 0.77 | TTK (0.45) | FLT3ADORA3TTK | |
| SCHEMBL5394360 | 0.76 | FLT3 (0.56) | FLT3ADORA3TTK | |
| SCHEMBL5403440 | 0.76 | FLT3 (0.59) | FLT3ADORA3TTKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12300526-B2 | Substrate processing control method, substrate processing apparatus and storage medium | TOKYO ELECTRON LIMITED (JP) | 2025-05-13 | — | — | US | disclosed |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | PHARMARON UK LTD. (GB) | 2024-05-09 | — | — | US | disclosed |
| US-20240087928-A1 | SUBSTRATE PROCESSING CONTROL METHOD, SUBSTRATE PROCESSING APPARATUS AND STORAGE MEDIUM | TOKYO ELECTRON LIMITED (JP) | 2024-03-14 | — | — | US | disclosed |
| US-11862496-B2 | Substrate processing control method, substrate processing apparatus and storage medium | TOKYO ELECTRON LIMITED (JP) | 2024-01-02 | — | — | US | disclosed |
| WO-2022189503-A1 | AN OPTOGENETIC VOLTAGE CLAMP (OVC) AND USES THEREOF | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2022-09-15 | — | — | WO | disclosed |
| EP-4056681-A1 | AN OPTOGENETIC VOLTAGE CLAMP (OVC) AND USES THEREOF | Johann Wolfgang Goethe-Universität Frankfurt (DE) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022159745-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| EP-2686319-B1 | IMIDAZO PYRAZINES | HOFFMANN LA ROCHE (CH) | 2016-07-13 | — | — | EP | disclosed |
| EP-2686319-B1 | IMIDAZO PYRAZINES | HOFFMANN LA ROCHE (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-8673905-B2 | Imidazo pyrazines | HOFFMANN-LA ROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | SUGEN, INC. | 2004-11-04 | — | — | US | disclosed |
| US-5028605-A | Antispasmodic, bronchodilators, uterine relaxants, cardiac analeptics, neurosedatives | L'UNIVERSITE DE MONTPELLIER I (FR) | 1991-07-02 | — | — | US | disclosed |
| EP-0348392-A1 | 8-ALKYLAMINOIMIDAZO[1,2-A]PYRAZINES AND DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | Université Montpellier I (FR) | 1990-01-03 | — | — | EP | disclosed |
| WO-1988004298-A1 | 8-ALKYLAMINOIMIDAZO[1,2-A]PYRAZINES AND DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | FLT3 4768/4885ADORA3 3528/4885IKBKB 3113/4885 |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | MAP3K8, MAP3K2, MAP3K5 | FLT3 216/4885ADORA3 2912/4885IKBKB 452/4885 |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | MAP3K8, MAP4K4, MAP3K2 | FLT3 215/4885ADORA3 2383/4885IKBKB 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.